ER Biz Model/Unit Economics
Anyone here actually understand unit economics of our business?
Like how much revenue does an II ranked and an average analyst generate from broker votes? Enough to cover the cost of their team?
Is ER really a cost center or is that just bc revenue gets accounted under S&T?
Is ER unprofitable without ECM activity? If so, why do banks cover sectors without any deal activity?
Based on the most helpful WSO content, here’s a breakdown of the unit economics and business model of Equity Research (ER):
Revenue Generation from Broker Votes:
Cost Coverage:
Profitability Without ECM Activity:
Why Banks Cover Low-Activity Sectors:
In summary, while ER may appear to be a cost center due to how revenue is accounted for, it plays a critical role in driving indirect revenue and supporting other banking functions. Its profitability often depends on the level of trading and deal activity in the sectors it covers.
Sources: Where does ER go from here?, Equity Research Q&A with Flake, Where are the raises for ER??, https://www.wallstreetoasis.com/forum/investment-banking/how-ibd-makes-or-loses-money-and-why-that-matters-to-you?customgpt=1, Help with Writing ER Reports for Beginners (Value Investing)
Great question and bump.
From my understanding even II ranked analysts are cost centers.
Do you think Josh Schimmer is creating $7 million in revs? For context Sage Kelly made this at the peak of his career (head of Jef HC IBD). Maybe Josh is but that’s only through ECM activities and as you may know Trump has basically fucked the IPO pipeline… I think Cantor fucked up and overpaid for him + Eric Schmidt.
But to answer your question, yes they can through ECM activities. I don’t think so much so on purely the research front. There are shops like Wolfe, but just so you know they also have ECM through SMBC (could be wrong on the shop). The
Wolfe’s alliance is with Nomura.
SMBC no longer has ECM after its alliance with Jefferies.
Saying Josh Schimmer and Eric Schmidt are major cost centers is about as myopic as it gets. Five years ago Cantor didn’t do any biotech deals and now they get ECM mandates on the regular. It doesn’t take that many deals to make up for their comp, to say nothing of broker votes and commissions. Yeah, they’re overpaid. But not by that much if you think about their jobs as franchise building. Cantor’s perceived emergence in the biotech world could outlast the careers of both guys if they play their cards right.
Vero nihil ex necessitatibus necessitatibus repellendus voluptates est. Repellendus provident ipsam error. A aliquid ut enim eaque beatae quibusdam. Perferendis excepturi quis ut.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...